MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
China Pharma Holdings Operating Expenses 2011-2025 | CPHI
Annual Operating Expenses China Pharma Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.6 M | 2.47 M | 3.06 M | 3.21 M | 4.42 M | 4.87 M | 5.34 M | 5.57 M | 6.33 M | 5.51 M | 7.8 M | 7.37 M | 6.71 M | 6.96 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.8 M | 2.47 M | 5.16 M |
Quarterly Operating Expenses China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 568 K | 565 K | 623 K | - | 566 K | 376 K | 626 K | - | 480 K | 310 K | 575 K | - | 551 K | 550 K | 742 K | - | 466 K | 824 K | 969 K | - | 1 M | 1.07 M | 794 K | - | 1.02 M | 917 K | 991 K | - | 2.44 M | 1.44 M | 1.19 M | - | 2.48 M | 2.78 M | 1.52 M | - | 1.9 M | 3.05 M | 1.96 M | - | -1.22 M | -1.49 M | 4.82 M | - | 7.57 M | 10.9 M | 5 M | - | 4.92 M | 6.91 M | 1.43 M | - | 1.63 M | 1.93 M | 1.89 M | - | 1.55 M | 1.67 M | 1.53 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.9 M | -1.49 M | 1.83 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.23 | -5.8 % | $ 132 M |  Canada |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M |  USA |
 |
Cronos Group
CRON
|
154 M | $ 2.69 | -1.83 % | $ 1.44 B | Canada |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 4.53 | -0.88 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 5.36 | -8.77 % | $ 706 M | USA |
 |
Emergent BioSolutions
EBS
|
558 M | $ 12.35 | -2.22 % | $ 632 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 26.35 | 1.27 % | $ 1.22 B | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.6 | 0.09 % | $ 2.06 B |  France |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.83 | 2.77 % | $ 19.4 M | USA |
 |
Solid Biosciences
SLDB
|
130 M | $ 5.89 | -0.17 % | $ 240 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.74 | -1.98 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.56 | -2.32 % | $ 4.42 M | USA |
 |
Evolus
EOLS
|
107 M | $ 6.74 | -1.6 % | $ 418 M | USA |
 |
Harrow Health
HROW
|
90.1 M | $ 50.46 | 0.61 % | $ 1.65 B | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.85 | 4.83 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 7.17 | -0.14 % | $ 2.62 B | Canada |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
44 M | $ 2.32 | -0.65 % | $ 313 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.19 | -0.24 % | $ 58.9 M | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
1.43 B | $ 13.8 | 0.36 % | $ 1.9 B | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | $ 0.52 | -14.85 % | $ 8.24 M | USA |
 |
Relmada Therapeutics
RLMD
|
104 M | $ 4.45 | -3.24 % | $ 134 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 1.71 | 4.91 % | $ 7.37 M | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 9.99 | 0.92 % | $ 710 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
67.5 M | $ 0.59 | -0.03 % | $ 28.2 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
1.52 B | $ 9.68 | -4.68 % | $ 5.98 B | Canada |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 1.71 | 0.68 % | $ 17.9 M | USA |
 |
Viatris
VTRS
|
4.88 B | $ 12.32 | 0.61 % | $ 14.9 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |